DIF-1 inhibits the Wnt/β-catenin signaling pathway by inhibiting TCF7L2 expression in colon cancer cell lines

Kentaro Jingushi, Fumi Takahashi-Yanaga, Tatsuya Yoshihara, Fumie Shiraishi, Yutaka Watanabe, Masato Hirata, Sachio Morimoto, Toshiyuki Sasaguri

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

We previously reported that differentiation-inducing factor-1 (DIF-1), a morphogen in Dictyostelium discoideum, inhibits the proliferation of human cancer cell lines by inducing β-catenin degradation and suppressing the Wnt/β-catenin signaling pathway. To determine whether β-catenin degradation is essential for the effect of DIF-1, we examined the effect of DIF-1 on human colon cancer cell lines (HCT-116, SW-620 and DLD-1), in which the Wnt/β-catenin signaling pathway is constitutively active. DIF-1 strongly inhibited cell proliferation and arrested the cell cycle in the G 0/G 1 phase via the suppression of cyclin D1 expression at mRNA and protein levels without reducing β-catenin protein. TCF-dependent transcriptional activity and cyclin D1 promoter activity were revealed to be inhibited via suppression of transcription factor 7-like 2 (TCF7L2) expression. Luciferase reporter assays and EMSAs using the TCF7L2 promoter fragments indicated that the binding site for the transcription factor early growth response-1 (Egr-1), which is located in the-609 to-601 bp region relative to the start codon in the TCF7L2 promoter, was involved in DIF-1 activity. Moreover, RNAi-mediated depletion of endogenous TCF7L2 resulted in reduced cyclin D1 promoter activity and protein expression, and the overexpression of TCF7L2 overrode the inhibition of the TCF-dependent transcriptional activity and cyclin D1 promoter activity induced by DIF-1. Therefore, DIF-1 seemed to inhibit the Wnt/β-catenin signaling pathway by suppressing TCF7L2 expression via reduced Egr-1-dependent transcriptional activity in these colon cancer cell lines. Our results provide a novel insight into the mechanisms by which DIF-1 inhibits the Wnt/β-catenin signaling pathway.

Original languageEnglish
Pages (from-to)47-56
Number of pages10
JournalBiochemical Pharmacology
Volume83
Issue number1
DOIs
Publication statusPublished - Jan 1 2012

Fingerprint

T Cell Transcription Factor 1
Catenins
Wnt Signaling Pathway
Colonic Neoplasms
Cells
Cell Line
Cyclin D1
Early Growth Response Protein 1
Degradation
Dictyostelium
Initiator Codon
1-((3,5-dichloro)-2,6-dihydroxy-4-methoxyphenyl)-1-hexanone
Cell proliferation
RNA Interference
Luciferases
Assays
Cell Cycle
Proteins
Binding Sites
Cell Proliferation

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Pharmacology

Cite this

DIF-1 inhibits the Wnt/β-catenin signaling pathway by inhibiting TCF7L2 expression in colon cancer cell lines. / Jingushi, Kentaro; Takahashi-Yanaga, Fumi; Yoshihara, Tatsuya; Shiraishi, Fumie; Watanabe, Yutaka; Hirata, Masato; Morimoto, Sachio; Sasaguri, Toshiyuki.

In: Biochemical Pharmacology, Vol. 83, No. 1, 01.01.2012, p. 47-56.

Research output: Contribution to journalArticle

Jingushi, K, Takahashi-Yanaga, F, Yoshihara, T, Shiraishi, F, Watanabe, Y, Hirata, M, Morimoto, S & Sasaguri, T 2012, 'DIF-1 inhibits the Wnt/β-catenin signaling pathway by inhibiting TCF7L2 expression in colon cancer cell lines', Biochemical Pharmacology, vol. 83, no. 1, pp. 47-56. https://doi.org/10.1016/j.bcp.2011.10.001
Jingushi, Kentaro ; Takahashi-Yanaga, Fumi ; Yoshihara, Tatsuya ; Shiraishi, Fumie ; Watanabe, Yutaka ; Hirata, Masato ; Morimoto, Sachio ; Sasaguri, Toshiyuki. / DIF-1 inhibits the Wnt/β-catenin signaling pathway by inhibiting TCF7L2 expression in colon cancer cell lines. In: Biochemical Pharmacology. 2012 ; Vol. 83, No. 1. pp. 47-56.
@article{7d79cdaaa9074657bbb5f25d2e4bc02e,
title = "DIF-1 inhibits the Wnt/β-catenin signaling pathway by inhibiting TCF7L2 expression in colon cancer cell lines",
abstract = "We previously reported that differentiation-inducing factor-1 (DIF-1), a morphogen in Dictyostelium discoideum, inhibits the proliferation of human cancer cell lines by inducing β-catenin degradation and suppressing the Wnt/β-catenin signaling pathway. To determine whether β-catenin degradation is essential for the effect of DIF-1, we examined the effect of DIF-1 on human colon cancer cell lines (HCT-116, SW-620 and DLD-1), in which the Wnt/β-catenin signaling pathway is constitutively active. DIF-1 strongly inhibited cell proliferation and arrested the cell cycle in the G 0/G 1 phase via the suppression of cyclin D1 expression at mRNA and protein levels without reducing β-catenin protein. TCF-dependent transcriptional activity and cyclin D1 promoter activity were revealed to be inhibited via suppression of transcription factor 7-like 2 (TCF7L2) expression. Luciferase reporter assays and EMSAs using the TCF7L2 promoter fragments indicated that the binding site for the transcription factor early growth response-1 (Egr-1), which is located in the-609 to-601 bp region relative to the start codon in the TCF7L2 promoter, was involved in DIF-1 activity. Moreover, RNAi-mediated depletion of endogenous TCF7L2 resulted in reduced cyclin D1 promoter activity and protein expression, and the overexpression of TCF7L2 overrode the inhibition of the TCF-dependent transcriptional activity and cyclin D1 promoter activity induced by DIF-1. Therefore, DIF-1 seemed to inhibit the Wnt/β-catenin signaling pathway by suppressing TCF7L2 expression via reduced Egr-1-dependent transcriptional activity in these colon cancer cell lines. Our results provide a novel insight into the mechanisms by which DIF-1 inhibits the Wnt/β-catenin signaling pathway.",
author = "Kentaro Jingushi and Fumi Takahashi-Yanaga and Tatsuya Yoshihara and Fumie Shiraishi and Yutaka Watanabe and Masato Hirata and Sachio Morimoto and Toshiyuki Sasaguri",
year = "2012",
month = "1",
day = "1",
doi = "10.1016/j.bcp.2011.10.001",
language = "English",
volume = "83",
pages = "47--56",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - DIF-1 inhibits the Wnt/β-catenin signaling pathway by inhibiting TCF7L2 expression in colon cancer cell lines

AU - Jingushi, Kentaro

AU - Takahashi-Yanaga, Fumi

AU - Yoshihara, Tatsuya

AU - Shiraishi, Fumie

AU - Watanabe, Yutaka

AU - Hirata, Masato

AU - Morimoto, Sachio

AU - Sasaguri, Toshiyuki

PY - 2012/1/1

Y1 - 2012/1/1

N2 - We previously reported that differentiation-inducing factor-1 (DIF-1), a morphogen in Dictyostelium discoideum, inhibits the proliferation of human cancer cell lines by inducing β-catenin degradation and suppressing the Wnt/β-catenin signaling pathway. To determine whether β-catenin degradation is essential for the effect of DIF-1, we examined the effect of DIF-1 on human colon cancer cell lines (HCT-116, SW-620 and DLD-1), in which the Wnt/β-catenin signaling pathway is constitutively active. DIF-1 strongly inhibited cell proliferation and arrested the cell cycle in the G 0/G 1 phase via the suppression of cyclin D1 expression at mRNA and protein levels without reducing β-catenin protein. TCF-dependent transcriptional activity and cyclin D1 promoter activity were revealed to be inhibited via suppression of transcription factor 7-like 2 (TCF7L2) expression. Luciferase reporter assays and EMSAs using the TCF7L2 promoter fragments indicated that the binding site for the transcription factor early growth response-1 (Egr-1), which is located in the-609 to-601 bp region relative to the start codon in the TCF7L2 promoter, was involved in DIF-1 activity. Moreover, RNAi-mediated depletion of endogenous TCF7L2 resulted in reduced cyclin D1 promoter activity and protein expression, and the overexpression of TCF7L2 overrode the inhibition of the TCF-dependent transcriptional activity and cyclin D1 promoter activity induced by DIF-1. Therefore, DIF-1 seemed to inhibit the Wnt/β-catenin signaling pathway by suppressing TCF7L2 expression via reduced Egr-1-dependent transcriptional activity in these colon cancer cell lines. Our results provide a novel insight into the mechanisms by which DIF-1 inhibits the Wnt/β-catenin signaling pathway.

AB - We previously reported that differentiation-inducing factor-1 (DIF-1), a morphogen in Dictyostelium discoideum, inhibits the proliferation of human cancer cell lines by inducing β-catenin degradation and suppressing the Wnt/β-catenin signaling pathway. To determine whether β-catenin degradation is essential for the effect of DIF-1, we examined the effect of DIF-1 on human colon cancer cell lines (HCT-116, SW-620 and DLD-1), in which the Wnt/β-catenin signaling pathway is constitutively active. DIF-1 strongly inhibited cell proliferation and arrested the cell cycle in the G 0/G 1 phase via the suppression of cyclin D1 expression at mRNA and protein levels without reducing β-catenin protein. TCF-dependent transcriptional activity and cyclin D1 promoter activity were revealed to be inhibited via suppression of transcription factor 7-like 2 (TCF7L2) expression. Luciferase reporter assays and EMSAs using the TCF7L2 promoter fragments indicated that the binding site for the transcription factor early growth response-1 (Egr-1), which is located in the-609 to-601 bp region relative to the start codon in the TCF7L2 promoter, was involved in DIF-1 activity. Moreover, RNAi-mediated depletion of endogenous TCF7L2 resulted in reduced cyclin D1 promoter activity and protein expression, and the overexpression of TCF7L2 overrode the inhibition of the TCF-dependent transcriptional activity and cyclin D1 promoter activity induced by DIF-1. Therefore, DIF-1 seemed to inhibit the Wnt/β-catenin signaling pathway by suppressing TCF7L2 expression via reduced Egr-1-dependent transcriptional activity in these colon cancer cell lines. Our results provide a novel insight into the mechanisms by which DIF-1 inhibits the Wnt/β-catenin signaling pathway.

UR - http://www.scopus.com/inward/record.url?scp=81855197038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81855197038&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2011.10.001

DO - 10.1016/j.bcp.2011.10.001

M3 - Article

C2 - 22005519

AN - SCOPUS:81855197038

VL - 83

SP - 47

EP - 56

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 1

ER -